Centessa Pharmaceuticals plc (CNTA)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
CNTA Insider Trading Activity
CNTA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $18,535,044 | 43 | 100 |
Related Transactions
| CHAO DAVID M | Chief Administrative Officer | 0 | $0 | 1 | $120,206 | $-120,206 |
| Bush Tia L | Chief Technology & Quality Ofc | 0 | $0 | 3 | $663,296 | $-663,296 |
| HUSSAIN IQBAL J | General Counsel | 0 | $0 | 4 | $1.56M | $-1.56M |
| Anderson Karen M. | Chief People Officer | 0 | $0 | 6 | $1.59M | $-1.59M |
| Weinhoff Gregory M | Chief Business Officer | 0 | $0 | 10 | $2.41M | $-2.41M |
| SAHA SAURABH | Chief Executive Officer | 0 | $0 | 19 | $12.19M | $-12.19M |
About Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Insider Activity of Centessa Pharmaceuticals plc
Over the last 12 months, insiders at Centessa Pharmaceuticals plc have bought $0 and sold $18.54M worth of Centessa Pharmaceuticals plc stock.
On average, over the past 5 years, insiders at Centessa Pharmaceuticals plc have bought $75.13M and sold $6.72M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $92,568 was made by SAHA SAURABH (Chief Executive Officer) on 2022‑06‑24.
List of Insider Buy and Sell Transactions, Centessa Pharmaceuticals plc
| 2025-03-20 | Sale | SAHA SAURABH | Chief Executive Officer | 55,000 0.0428% | $16.69 | $918,060 | -5.64% | |
| 2025-03-17 | Sale | CHAO DAVID M | Chief Administrative Officer | 7,000 0.0053% | $17.17 | $120,206 | -4.71% | |
| 2025-03-17 | Sale | HUSSAIN IQBAL J | General Counsel | 6,000 0.0044% | $16.45 | $98,697 | -4.71% | |
| 2025-02-25 | Sale | Weinhoff Gregory M | Chief Business Officer | 11,494 0.008% | $15.25 | $175,270 | +4.13% | |
| 2025-02-20 | Sale | SAHA SAURABH | Chief Executive Officer | 55,000 0.0418% | $15.93 | $876,088 | +3.09% | |
| 2025-02-18 | Sale | HUSSAIN IQBAL J | General Counsel | 6,000 0.0043% | $16.18 | $97,065 | -2.80% | |
| 2025-02-10 | Sale | Anderson Karen M. | Chief People Officer | 429 0.0003% | $18.99 | $8,147 | -6.22% | |
| 2025-02-07 | Sale | Anderson Karen M. | Chief People Officer | 30,526 0.0247% | $19.03 | $580,797 | -13.45% | |
| 2025-02-03 | Sale | Bush Tia L | Chief Technology & Quality Ofc | 11,000 0.0083% | $16.86 | $185,406 | -2.31% | |
| 2025-02-03 | Sale | Anderson Karen M. | Chief People Officer | 6,471 0.0049% | $16.86 | $109,124 | -2.31% | |
| 2025-01-27 | Sale | Weinhoff Gregory M | Chief Business Officer | 11,742 0.009% | $16.47 | $193,429 | +2.07% | |
| 2025-01-21 | Sale | SAHA SAURABH | Chief Executive Officer | 55,000 0.0401% | $15.77 | $867,430 | +1.06% | |
| 2025-01-15 | Sale | HUSSAIN IQBAL J | General Counsel | 6,000 0.0045% | $15.29 | $91,740 | +7.21% | |
| 2024-12-26 | Sale | Weinhoff Gregory M | Chief Business Officer | 10,000 0.0075% | $17.04 | $170,399 | -4.35% | |
| 2024-12-20 | Sale | SAHA SAURABH | Chief Executive Officer | 55,000 0.0422% | $17.44 | $959,057 | -3.06% | |
| 2024-12-17 | Sale | Bush Tia L | Chief Technology & Quality Ofc | 17,813 0.0138% | $18.00 | $320,634 | -5.23% | |
| 2024-12-17 | Sale | Anderson Karen M. | Chief People Officer | 10,624 0.0079% | $17.32 | $184,036 | -5.23% | |
| 2024-12-16 | Sale | Bush Tia L | Chief Technology & Quality Ofc | 9,611 0.0072% | $16.36 | $157,256 | -0.24% | |
| 2024-12-16 | Sale | HUSSAIN IQBAL J | General Counsel | 77,705 0.0585% | $16.39 | $1.27M | -0.24% | |
| 2024-12-13 | Sale | Anderson Karen M. | Chief People Officer | 5,876 0.0045% | $17.01 | $99,974 | +1.03% |
Insider Historical Profitability
| SAHA SAURABH | Chief Executive Officer | 276017 0.2096% | $4.35M | 3 | 19 | <0.0001% |
| CHAO DAVID M | Chief Administrative Officer | 225007 0.1709% | $3.54M | 1 | 3 | <0.0001% |
| Weinhoff Gregory M | Chief Business Officer | 134021 0.1018% | $2.11M | 1 | 12 | <0.0001% |
| Bush Tia L | Chief Technology & Quality Ofc | 121503 0.0923% | $1.91M | 2 | 6 | <0.0001% |
| HUSSAIN IQBAL J | General Counsel | 105386 0.08% | $1.66M | 1 | 6 | <0.0001% |
| Anderson Karen M. | Chief People Officer | 54322 0.0413% | $855,571.50 | 0 | 6 | |
| GAP (Bermuda) LTD | 10 percent owner | 9681818 7.3537% | $152.49M | 1 | 0 | <0.0001% |
| De Rubertis Francesco | director | 3936970 2.9903% | $62.01M | 6 | 0 | <0.0001% |
| Medicxi Ventures Management (Jersey) Ltd | 10 percent owner | 3936970 2.9903% | $62.01M | 6 | 0 | <0.0001% |
| GOYAL ARJUN | director | 3825659 2.9057% | $60.25M | 1 | 0 | <0.0001% |
| GRAINGER DAVID J | Chief Innovation Officer | 908575 0.6901% | $14.31M | 1 | 2 | <0.0001% |
| YVER ANTOINE | EVP & Chairman of Development | 783066 0.5948% | $12.33M | 0 | 17 | |
| Shahidi Javad | Chief Medical Officer | 158932 0.1207% | $2.5M | 0 | 2 | |
| Templeman Thomas | Chief Technology Officer | 135792 0.1031% | $2.14M | 1 | 2 | <0.0001% |
| Rotman Harris | SVP Regulatory Affairs | 62625 0.0476% | $986,343.75 | 0 | 2 | |
| KANTOFF AARON | director | 60000 0.0456% | $945,000.00 | 1 | 0 | <0.0001% |
| Thorell Marella | Chief Accounting Officer | 1000 0.0008% | $15,750.00 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$66,492,695 | 135 | 27.65% | $2.08B | |
$1,376,668 | 53 | 18.46% | $2.31B | |
$11,583,737 | 45 | 49.75% | $1.82B | |
$224,319,161 | 41 | 27.46% | $2.3B | |
$148,770,544 | 34 | 80.63% | $1.73B | |
$62,927,079 | 29 | 14.02% | $2.25B | |
Centessa Pharmaceuticals plc (CNTA) | $150,253,463 | 26 | -52.83% | $2.07B |
$1,801,511 | 23 | 18.58% | $2.03B | |
$154,554,190 | 14 | 29.60% | $1.79B | |
$92,580,864 | 14 | -1.28% | $2.25B | |
$75,296,816 | 12 | 37.23% | $2.11B | |
$128,232,675 | 11 | 134.40% | $1.77B | |
$137,013,690 | 11 | 26.62% | $2.02B | |
$32,575,266 | 8 | 37.03% | $2.08B | |
$25,073,947 | 7 | -5.99% | $2.02B | |
$142,493,653 | 3 | 4.30% | $1.7B | |
$7,600,000 | 1 | -4.05% | $2.08B | |
$9,900,000 | 1 | -7.19% | $2.1B | |
$10,000,009 | 1 | 100.92% | $1.81B |
CNTA Institutional Investors: Active Positions
| Increased Positions | 61 | +51.26% | 15M | +12.48% |
| Decreased Positions | 51 | -42.86% | 9M | -7.52% |
| New Positions | 25 | New | 3M | New |
| Sold Out Positions | 15 | Sold Out | 5M | Sold Out |
| Total Postitions | 129 | +8.4% | 124M | +4.96% |
CNTA Ownership Change vs Market
Institutional Investor Ownership
| Medicxi Ventures Management (Jersey) Ltd | $342,169.00 | 17.51% | 19.96M | 0 | 0% | 2024-12-31 |
| Index Venture Life Associates Vi Ltd | $170,745.00 | 8.74% | 9.96M | 0 | 0% | 2024-12-31 |
| General Atlantic, L.P. | $165,946.00 | 8.49% | 9.68M | 0 | 0% | 2024-12-31 |
| Perceptive Advisors Llc | $108,826.00 | 5.57% | 6.35M | +66,930 | +1.06% | 2024-12-31 |
| First Light Asset Management, Llc | $99,501.00 | 5.09% | 5.81M | -134,948 | -2.27% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $91,946.00 | 4.71% | 5.36M | +685,371 | +14.65% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $87,740.00 | 4.49% | 5.12M | +924,027 | +22.03% | 2024-12-31 |
| Janus Henderson Group Plc | $84,149.00 | 4.31% | 4.91M | +4M | +279.15% | 2024-12-31 |
| Vida Ventures Advisors, Llc | $67,391.00 | 3.45% | 3.93M | 0 | 0% | 2024-12-31 |
| Fmr Llc | $62,588.00 | 3.2% | 3.65M | +735,100 | +25.2% | 2024-12-31 |